Living CTE Diagnosis: NFL Players Face Career-Defining Choice as Science Advances

For decades, chronic traumatic encephalopathy has existed in a diagnostic void for the living. The degenerative brain disease associated with repeated head trauma can currently only be confirmed through postmortem examination, leaving thousands of former and current NFL players to navigate debilitating symptoms without medical certainty. That paradigm is shifting as researchers enter the second phase of clinical trials aimed at detecting CTE biomarkers in living patients, a development that promises clarity but forces an unprecedented ethical reckoning within professional football.

The urgency for antemortem testing extends beyond scientific curiosity. A 2024 study revealed that nearly one-third of former NFL players experiencing general health issues incorrectly attribute their symptoms to CTE. This misattribution carries severe consequences: players who believe they have the disease are five times more likely to experience suicidal ideation than those who do not. Many conditions mimicking CTE symptoms, including sleep apnea, depression, hypertension, and low testosterone, are treatable. Without a definitive diagnosis, players may suffer needlessly while ignoring manageable medical conditions.

Boston University neuropsychologist Michael Alosco, leading government-funded research through the Diagnose CTE Research Project, indicates the field is approaching a breakthrough. His team is analyzing data from over 300 former players and non-player controls aged 50 and older, searching for consistent biological patterns that distinguish CTE from other neurodegenerative disorders. While no timeline exists for clinical availability, the transition from postmortem confirmation to living diagnosis represents the most significant advancement in sports neurology since CTE was first identified in athletes.

Current and former players express starkly divided reactions to the prospect of knowing their status while still active. Washington Commanders quarterback Marcus Mariota and Dallas Cowboys safety Malik Hooker view testing as a responsibility to themselves, their families, and future generations of athletes. For these players, knowledge enables prevention strategies and informed life planning. Pittsburgh Steelers safety DeShon Elliott similarly emphasized the value of early detection for mitigation purposes.

Others fear the psychological and professional toll of premature knowledge. Indianapolis Colts tight end Mo Alie-Cox worries about stigma and altered treatment from teammates and coaches, preferring to wait until symptoms become undeniable. Minnesota Vikings safety Joshua Metellus acknowledged that a positive result would fundamentally alter his playing style or force retirement, creating a deterrent to testing while employed. Several anonymous players admitted they would continue playing regardless of results due to competitive drive, financial necessity, or skepticism about emerging science’s reliability.

This division reflects a deeper tension between individual autonomy and institutional liability. If a reliable test becomes available, the NFL could face pressure to mandate screening as part of preseason physicals, similar to existing cardiac and orthopedic evaluations. Carolina Panthers long snapper JJ Jansen noted that players already undergo extensive biological testing, making neurological assessment a logical extension. However, mandatory testing raises complex questions about employment discrimination, insurance eligibility, and whether teams might use results to justify roster decisions.

The experiences of former players like Larry Johnson underscore what remains at stake. The 46-year-old former Kansas City Chiefs running back describes severe short-term memory loss, spatial disorientation, and emotional dysregulation consistent with CTE. Yet without antemortem confirmation, he cannot access targeted interventions or participate in clinical trials designed specifically for CTE patients. His uncertainty mirrors that of countless retirees who donated their brains to science hoping to spare others from similar ambiguity.

Researchers caution that even successful biomarker identification will not immediately translate to treatment protocols. CTE pathology involves tau protein accumulation distinct from Alzheimer’s disease, requiring separate therapeutic approaches. Current management focuses on symptom relief rather than disease modification. Nevertheless, accurate diagnosis would enable appropriate counseling, eliminate dangerous self-diagnosis, and establish baseline data essential for developing future treatments.

The next phase of the Diagnose CTE Research Project continues recruiting participants across multiple sites, with findings expected to inform FDA regulatory pathways for diagnostic approval.